Pfizer (NYSE: PFE) is set to report third-quarter results on Nov. 4, with analysts at Leerink Partners lowering earnings forecasts ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Hot List Hot List Pro

Pfizer Files Federal Antitrust Claims in Second Lawsuit Against Metsera, its Controlling Stockholders and Novo NordiskNovember 3, 2025 9:58 AM Pfizer accuses Novo Nordisk of anticompetitive plot to stall Metsera deal in lawsuitNovember 3, 2025 8:20 AM Pfizer files second lawsuit against Novo Nordisk over Metsera acquisitionNovember 3, 2025 8:16 AM Metsera responds to Pfizer litigation, will address claims in courtNovember 3, 2025 3:53 AM Pfizer sues Metsera directors and Novo Nordisk over merger breachOctober 31, 2025 4:37 PM Pfizer Files Lawsuit Against Metsera and its Directors and Novo Nordisk for Breach of Merger AgreementOctober 31, 2025 4:37 PM Pfizer gets early FTC clearance for Metsera acquisitionOctober 31, 2025 3:51 PM Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera AcquisitionOctober 31, 2025 3:50 PM Bernstein SocGen Group Reiterates Market Perform Rating on Pfizer (PFE), 'a sore loss for Pfizer' if Novo are successful in bid for MetseraOctober 31, 2025 8:57 AM Pfizer said to mull suing Novo Nordisk over Metsera bidOctober 30, 2025 1:52 PM Pfizer mulls suing Metsera, Novo Nordisk over topping bid - SemaforOctober 30, 2025 1:38 PM Metsera Was Previously in Exclusive Talks with Bristol-Myers Squibb, Sources Say -- WSJOctober 30, 2025 12:56 PM Novo Nodrisk stock dips on aggressive odder to buy Metsera, 'reckless' says PfizerOctober 30, 2025 8:47 AM Pfizer calls Novo Nordisk's Metsera bid reckless and illegalOctober 30, 2025 6:57 AM Pfizer Addresses Proposal for MetseraOctober 30, 2025 6:57 AM